Subjects -> MEDICAL SCIENCES (Total: 8529 journals)
    - ANAESTHESIOLOGY (120 journals)
    - CARDIOVASCULAR DISEASES (332 journals)
    - DENTISTRY (292 journals)
    - ENDOCRINOLOGY (150 journals)
    - FORENSIC SCIENCES (41 journals)
    - HEMATOLOGY (155 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (167 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2342 journals)
    - NURSES AND NURSING (362 journals)
    - OBSTETRICS AND GYNECOLOGY (207 journals)
    - ONCOLOGY (381 journals)
    - OTORHINOLARYNGOLOGY (82 journals)
    - PATHOLOGY (98 journals)
    - PEDIATRICS (273 journals)
    - PSYCHIATRY AND NEUROLOGY (822 journals)
    - RESPIRATORY DISEASES (103 journals)
    - RHEUMATOLOGY (78 journals)
    - SPORTS MEDICINE (81 journals)
    - SURGERY (401 journals)

RESPIRATORY DISEASES (103 journals)                     

Showing 1 - 104 of 104 Journals sorted alphabetically
Advances in Respiratory Medicine     Open Access   (Followers: 7)
Advances in Thoracic Diseases     Open Access   (Followers: 1)
American Journal of Respiratory and Critical Care Medicine     Full-text available via subscription   (Followers: 259)
American Journal of Respiratory Cell and Molecular Biology     Full-text available via subscription   (Followers: 20)
American Review of Respiratory Disease     Full-text available via subscription   (Followers: 4)
Angiologia e Cirurgia Vascular     Open Access   (Followers: 1)
Annals of the American Thoracic Society     Full-text available via subscription   (Followers: 17)
Annals of Thoracic Medicine     Open Access   (Followers: 6)
Archives of Pulmonology and Respiratory Care     Open Access   (Followers: 2)
Archivos de Bronconeumología     Full-text available via subscription  
Archivos de Bronconeumología (English Edition)     Full-text available via subscription   (Followers: 1)
Asthma Research and Practice     Open Access   (Followers: 1)
BMC Pulmonary Medicine     Open Access   (Followers: 5)
BMJ Open Respiratory Research     Open Access   (Followers: 6)
Breathe     Open Access   (Followers: 4)
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine     Hybrid Journal   (Followers: 1)
Canadian Respiratory Journal     Open Access   (Followers: 3)
Case Reports in Pulmonology     Open Access   (Followers: 3)
Chest     Full-text available via subscription   (Followers: 102)
Chest Disease Reports     Open Access   (Followers: 2)
Chronic Respiratory Disease     Hybrid Journal   (Followers: 9)
Clinical Lung Cancer     Hybrid Journal   (Followers: 6)
Clinical Medicine Insights : Circulatory, Respiratory and Pulmonary Medicine     Open Access   (Followers: 3)
Clinical Pulmonary Medicine     Hybrid Journal   (Followers: 2)
COPD Research and Practice     Open Access   (Followers: 1)
COPD: Journal of Chronic Obstructive Pulmonary Disease     Hybrid Journal   (Followers: 15)
Current Opinion in Pulmonary Medicine     Hybrid Journal   (Followers: 10)
Current Pulmonology Reports     Hybrid Journal  
Current Research in Tuberculosis     Open Access   (Followers: 3)
Current Respiratory Care Reports     Hybrid Journal   (Followers: 1)
Current Respiratory Medicine Reviews     Hybrid Journal   (Followers: 5)
Der Pneumologe     Hybrid Journal   (Followers: 1)
Egyptian Journal of Chest Diseases and Tuberculosis     Open Access   (Followers: 3)
ERJ Open Research     Open Access   (Followers: 3)
Eurasian Journal of Pulmonology     Open Access  
European Clinical Respiratory Journal     Open Access   (Followers: 3)
European Respiratory Journal     Full-text available via subscription   (Followers: 39)
European Respiratory Review     Open Access   (Followers: 7)
Experimental Lung Research     Hybrid Journal  
Expert Review of Respiratory Medicine     Hybrid Journal   (Followers: 5)
Heart & Lung: The Journal of Acute and Critical Care     Hybrid Journal   (Followers: 13)
Heart, Lung and Circulation     Full-text available via subscription   (Followers: 9)
Indian Journal of Respiratory Care     Open Access   (Followers: 3)
Indian Journal of Tuberculosis     Full-text available via subscription  
Influenza and Other Respiratory Viruses     Open Access   (Followers: 3)
International Journal of Chronic Obstructive Pulmonary Disease     Open Access   (Followers: 3)
Journal of Association of Chest Physicians     Open Access   (Followers: 2)
Journal of Asthma     Hybrid Journal   (Followers: 4)
Journal of Asthma Allergy Educators     Hybrid Journal   (Followers: 4)
Journal of Bronchology & Interventional Pulmonology     Hybrid Journal   (Followers: 4)
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases     Open Access  
Journal of Heart and Lung Transplantation     Hybrid Journal   (Followers: 12)
Journal of Respiratory Medicine     Open Access   (Followers: 4)
Journal of Respiratory Research     Open Access   (Followers: 1)
Journal of Tuberculosis Research     Open Access   (Followers: 1)
Jurnal Respirasi     Open Access  
Karger Kompass Pneumologie     Full-text available via subscription   (Followers: 1)
Kindheit und Entwicklung     Hybrid Journal  
Lung     Hybrid Journal   (Followers: 2)
Lung Cancer     Hybrid Journal   (Followers: 16)
Lung Cancer International     Open Access   (Followers: 2)
Lung Cancer: Targets and Therapy     Open Access   (Followers: 3)
Lung India     Open Access   (Followers: 1)
Multidisciplinary Respiratory Medicine     Open Access   (Followers: 4)
npj Primary Care Respiratory Medicine     Open Access   (Followers: 2)
Open Journal of Respiratory Diseases     Open Access   (Followers: 1)
Open Respiratory Medicine Journal     Open Access   (Followers: 1)
Paediatric Respiratory Reviews     Hybrid Journal   (Followers: 11)
Pediatric Quality & Safety     Open Access  
Pediatric Respirology and Critical Care Medicine     Open Access   (Followers: 1)
Pulmonary Circulation     Open Access   (Followers: 4)
Pulmonary Medicine     Open Access   (Followers: 2)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pulmonary Therapy     Open Access   (Followers: 1)
Pulmonology and Respiratory Research     Open Access   (Followers: 1)
Respiratory Care     Full-text available via subscription   (Followers: 10)
Respiratory Investigation     Full-text available via subscription  
Respiratory Medicine     Hybrid Journal   (Followers: 18)
Respiratory Medicine : X     Open Access  
Respiratory Medicine Case Reports     Open Access  
Respiratory Medicine CME     Hybrid Journal  
Respiratory Medicine Extra     Full-text available via subscription   (Followers: 1)
Respiratory Physiology & Neurobiology     Hybrid Journal   (Followers: 4)
Respiratory Research     Open Access   (Followers: 1)
Respirology     Hybrid Journal   (Followers: 5)
Respirology Case Reports     Open Access  
Revista Americana de Medicina Respiratoria     Open Access  
Revista Chilena de Enfermedades Respiratorias     Open Access  
Revista Inspirar     Open Access  
Revista ORL     Open Access  
Revista Portuguesa de Pneumologia     Open Access  
Sarcoidosis Vasculitis and Diffuse Lung Disese     Full-text available via subscription   (Followers: 3)
Seminars in Respiratory and Critical Care Medicine     Hybrid Journal   (Followers: 14)
Sleep Medicine Reviews     Hybrid Journal   (Followers: 17)
The Clinical Respiratory Journal     Hybrid Journal   (Followers: 3)
The International Journal of Tuberculosis and Lung Disease     Full-text available via subscription   (Followers: 8)
The Lancet Respiratory Medicine     Full-text available via subscription   (Followers: 35)
Therapeutic Advances in Chronic Disease     Open Access   (Followers: 7)
Therapeutic Advances in Respiratory Disease     Open Access   (Followers: 1)
Thorax     Hybrid Journal   (Followers: 38)
Translational Respiratory Medicine     Open Access   (Followers: 1)
Tuberculosis     Hybrid Journal   (Followers: 12)
Tuberculosis Research and Treatment     Open Access   (Followers: 3)
Пульмонология     Full-text available via subscription  


Similar Journals
Journal Cover
European Respiratory Review
Journal Prestige (SJR): 1.973
Citation Impact (citeScore): 4
Number of Followers: 7  

  This is an Open Access Journal Open Access journal
ISSN (Print) 0905-9180 - ISSN (Online) 1600-0617
Published by European Respiratory Society Homepage  [4 journals]
  • Is bronchiectasis really a disease'

    • Authors: Shteinberg, M; Flume, P. A, Chalmers, J. D.
      Pages: 190051 - 190051
      Abstract: The definition of a disease requires that distinguishing signs and symptoms are present that are common, and that the constellation of signs and symptoms differentiate the condition from other causes. In bronchiectasis, anatomical changes, airways inflammation and airway infection are the distinguishing features that are common to this disease. However, bronchiectasis is a heterogenous disease: signs and symptoms are shared with other airway diseases, there are multiple aetiologies and certain phenotypes of bronchiectasis have distinct clinical and laboratory features that are not common to all people with bronchiectasis. Furthermore, response to therapeutic interventions in clinical trials is not uniform. The concept of bronchiectasis as a treatable trait has been suggested, but this may be too restrictive in view of the heterogeneity of bronchiectasis. It is our opinion that bronchiectasis should be defined as a disease in its own right, but one that shares several pathophysiological features and "treatable traits" with other airway diseases. These traits define the large heterogeneity in the pathogenesis and clinical features and suggest a more targeted approach to therapy.
      Keywords: CF and non-CF bronchiectasis
      PubDate: 2020-01-29T00:05:04-08:00
      DOI: 10.1183/16000617.0051-2019
      Issue No: Vol. 29, No. 155 (2020)
  • Current and future applications of liquid biopsy in nonsmall cell lung
           cancer from early to advanced stages

    • Authors: Guibert, N; Pradines, A, Favre, G, Mazieres, J.
      Pages: 190052 - 190052
      Abstract: Liquid biopsy refers to the analysis of any tumour-derived material circulating in the blood or any other body fluid. This concept is particularly relevant in lung cancer as the tumour is often difficult to reach and may need an invasive and potentially harmful procedure. Moreover, the multitude of anticancer drugs and their sequential use underline the importance of conducting an iterative assessment of tumour biology. Liquid biopsies can noninvasively detect any targetable genomic alteration and guide corresponding targeted therapy, in addition to monitoring response to treatment and exploring the genetic changes at resistance, overcoming spatial and temporal heterogeneity.In this article, we review the available data in the field, which suggest the potential of liquid biopsy in the area of lung cancer, with a particular focus on cell-free DNA and circulating tumour cells. We discuss their respective applications in patient selection and monitoring through targeted therapy, as well as immune checkpoint inhibitors. The current data and future applications of liquid biopsy in the early stage setting are also investigated.Liquid biopsy has the potential to help manage nonsmall cell lung cancer throughout all stages of lung cancer: screening, minimal residual disease detection to guide adjuvant treatment, early detection of relapse, systemic treatment initiation and monitoring of response (targeted or immune therapy), and resistance genotyping.
      Keywords: Lung cancer
      PubDate: 2020-02-12T00:09:10-08:00
      DOI: 10.1183/16000617.0052-2019
      Issue No: Vol. 29, No. 155 (2020)
  • The effects of pharmacological interventions on quality of life and
           fatigue in sarcoidosis: a systematic review

    • Authors: Vis, R; van de Garde, E. M. W, Grutters, J. C, Korenromp, I. H. E.
      Pages: 190057 - 190057
      Abstract: AimsMany sarcoidosis patients experience a reduction in health-related quality of life (HRQoL) and a majority of patients report fatigue. Historically, drug trials in sarcoidosis have focused on changes in chest radiographs, lung function parameters and biomarkers, while HRQoL and fatigue have not been the main outcomes examined. We performed a systematic review of the literature to evaluate the existing evidence on the effects of pharmacological interventions on HRQoL and fatigue outcomes.MethodsThe systematic search was performed in Medline and Embase and yielded 15 records covering seven randomised controlled trials and seven single-arm open label studies, which were included in a qualitative synthesis (the results of one study were included in two publications). 12 studies evaluated immunosuppressive and/or immunomodulatory therapies and two studies evaluated stimulants.ResultsNine out of the 14 studies observed positive treatment effects from the interventions on HRQoL and/or fatigue, exceeding the minimal important difference. The risk of bias was generally high with only three studies rated as having a low risk of bias. The results suggest a potential for improvement in HRQoL and/or fatigue in patients with active disease who are either untreated or treated but not yet fully stabilised or therapy refractory.ConclusionMore randomised, double-blind and placebo-controlled trials are needed to expand the evidence base on these important outcome parameters.
      Keywords: Pulmonary pharmacology and therapeutics
      PubDate: 2020-01-29T00:05:04-08:00
      DOI: 10.1183/16000617.0057-2019
      Issue No: Vol. 29, No. 155 (2020)
  • {alpha}1-Antitrypsin deficiency and chronic respiratory disorders

    • Authors: Cazzola, M; Stolz, D, Rogliani, P, Matera, M. G.
      Pages: 190073 - 190073
      Abstract: α1-antitrypsin deficiency (AATD) is a hereditary disorder associated with a risk of developing liver disease and pulmonary emphysema, and other chronic respiratory disorders (mainly asthma and bronchiectasis); Z variant is the commonest deficient variant of AAT. Determining AAT concentration in serum or plasma and identifying allelic variants by phenotyping or genotyping are fundamental in the diagnosis of AATD. Initial evaluation and annual follow-up measurement of lung function, including post-bronchodilator forced expiratory volume in 1 s and gas transfer inform on disease progression. Lung densitometry is the most sensitive measure of emphysema progression, but must not be use in the follow-up of patients in routine clinical practice. The exogenous administration of purified human serum-derived AAT is the only approved specific treatment for AATD in PiZZ. AAT augmentation therapy is not recommended in PiSZ, PiMZ or current smokers of any protein phenotype, or in patients with hepatic disease. Lung volume reduction and endoscopic bronchial valve placement are useful in selected patients, whereas the survival benefit of lung transplant is unclear. There are several new lines of research in AATD to improve the diagnosis and evaluation of the response to therapy and to develop genetic and regenerative therapies and other treatments.
      Keywords: COPD and smoking, Genetics
      PubDate: 2020-02-12T00:09:10-08:00
      DOI: 10.1183/16000617.0073-2019
      Issue No: Vol. 29, No. 155 (2020)
  • How can we minimise the use of regular oral corticosteroids in asthma'

    • Authors: Bourdin, A; Adcock, I, Berger, P, Bonniaud, P, Chanson, P, Chenivesse, C, de Blic, J, Deschildre, A, Devilliers, P, Devouassoux, G, Didier, A, Garcia, G, Magnan, A, Martinat, Y, Perez, T, Roche, N, Taille, C, Val, P, Chanez, P.
      Pages: 190085 - 190085
      Abstract: Options to achieve oral corticosteroid (OCS)-sparing have been triggering increasing interest since the 1970s because of the side-effects of OCSs, and this has now become achievable with biologics. The Société de Pneumologie de Langue Francaise workshop on OCSs aimed to conduct a comprehensive review of the basics for OCS use in asthma and issue key research questions. Pharmacology and definition of regular use were reviewed by the first working group (WG1). WG2 examined whether regular OCS use is associated with T2 endotype. WG3 reported on the specificities of the paediatric area. Key "research statement proposals" were suggested by WG4. It was found that the benefits of regular OCS use in asthma outside episodes of exacerbations are poorly supported by the existing evidence. However, complete OCS elimination couldn’t be achieved in any available studies for all patients and the panel felt that it was too early to conclude that regular OCS use could be declared criminal. Repeated or prolonged need for OCS beyond 1 g·year–1 should indicate the need for referral to secondary/tertiary care. A strategic sequential plan aiming at reducing overall exposure to OCS in severe asthma was then held as a conclusion of the workshop.
      Keywords: Asthma and allergy
      PubDate: 2020-02-05T01:40:07-08:00
      DOI: 10.1183/16000617.0085-2019
      Issue No: Vol. 29, No. 155 (2020)
  • Schistosomiasis-associated pulmonary arterial hypertension: a systematic

    • Authors: Knafl, D; Gerges, C, King, C. H, Humbert, M, Bustinduy, A. L.
      Pages: 190089 - 190089
      Abstract: Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) is a life-threatening complication of chronic hepatosplenic schistosomiasis. It is suggested to be the leading cause of pulmonary arterial hypertension (PAH) worldwide. However, pathophysiological data on Sch-PAH are scarce. We examined the hypothesis that there are pronounced similarities in pathophysiology, haemodynamics, and survival of Sch-PAH and idiopathic PAH (iPAH).This systematic review and meta-analysis was registered in the PROSPERO database (identifier CRD42018104066). A systematic search and review of the literature was performed according to PRISMA guidelines for studies published between 01 January 1990 and 29 June 2018.For Sch-PAH, 18 studies evaluating pathophysiological mechanisms, eight studies on haemodynamics (n=277), and three studies on survival (n=191) were identified. 16 clinical registries reporting data on haemodynamics and survival including a total of 5792 patients with iPAH were included for comparison. Proinflammatory molecular pathways are involved in both Sch-PAH and iPAH. The transforming growth factor (TGF)-β signalling pathway is upregulated in Sch-PAH and iPAH. While there was no difference in mean pulmonary artery pressure (54±17 mmHg versus 55±15 mmHg, p=0.29), cardiac output (4.4±1.3 L·min–1 versus 4.1±1.4 L·min–1, p=0.046), and cardiac index (2.6±0.7 L·min–1·m–2 versus 2.3±0.8 L·min–1·m–2, p
      Keywords: Pulmonary vascular disease
      PubDate: 2020-02-05T01:40:07-08:00
      DOI: 10.1183/16000617.0089-2019
      Issue No: Vol. 29, No. 155 (2020)
  • Shared mechanisms of multimorbidity in COPD, atherosclerosis and type-2
           diabetes: the neutrophil as a potential inflammatory target

    • Authors: Hughes, M. J; McGettrick, H. M, Sapey, E.
      Pages: 190102 - 190102
      Abstract: Multimorbidity is increasingly common and current healthcare strategies are not always aligned to treat this complex burden of disease. COPD, type-2 diabetes mellitus (T2D) and cardiovascular disease, especially atherosclerosis, occur more frequently together than expected, even when risk factors such as smoking, obesity, inactivity and poverty are considered. This supports the possibility of unifying mechanisms that contribute to the pathogenesis or progression of each condition.Neutrophilic inflammation is causally associated with COPD, and increasingly recognised in the pathogenesis of atherosclerosis and T2D, potentially forming an aetiological link between conditions. This link might reflect an overspill of inflammation from one affected organ into the systemic circulation, exposing all organs to an increased milieu of proinflammatory cytokines. Additionally, increasing evidence supports the involvement of other processes in chronic disease pathogenesis, such as cellular senescence or changes in cellular phenotypes.This review explores the current scientific evidence for inflammation, cellular ageing and cellular processes, such as reactive oxygen species production and phenotypic changes in the pathogenesis of COPD, T2D and atherosclerosis; highlighting common mechanisms shared across these diseases. We identify emerging therapeutic approaches that target these areas, but also where more work is still required to improve our understanding of the underlying cellular biology in a multimorbid disease setting.
      Keywords: COPD and smoking
      PubDate: 2020-03-20T03:42:55-07:00
      DOI: 10.1183/16000617.0102-2019
      Issue No: Vol. 29, No. 155 (2020)
  • Subglottic secretion drainage for preventing ventilator-associated

    • Authors: Pozuelo-Carrascosa, D. P; Herraiz-Adillo, A, Alvarez-Bueno, C, Anon, J. M, Martinez-Vizcaino, V, Cavero-Redondo, I.
      Pages: 190107 - 190107
      Abstract: Although several guidelines recommend subglottic secretion drainage as a strategy for prevention of ventilator-associated pneumonia (VAP), its use is not widespread. With the aim to assess the effectiveness of subglottic secretion drainage for preventing VAP and to improve other outcomes such as mortality, duration of mechanical ventilation and length of stay in the intensive care unit (ICU) or hospital, an electronic search of the Cochrane Library, MEDLINE, Web of Science and Embase was undertaken. Nine systematic reviews with meta-analysis (in the overview of reviews) and 20 randomised controlled trials (in the updated meta-analysis) were included.In the overview of reviews, all systematic reviews with meta-analysis included found a positive effect of subglottic secretion drainage in the reduction of incidence of VAP. In the updated meta-analysis, subglottic secretion drainage significantly reduced VAP incidence (risk ratio (RR) 0.56, 95% CI 0.48–0.63; I2=0%, p=0.841) and mortality (RR 0.88, 95% CI 0.80–0.97; I2=0%, p=0.888).This is the first study that has found a decrease of mortality associated with the use of subglottic secretion drainage. In addition, subglottic secretion drainage is an effective measure to reduce VAP incidence, despite not improving the duration of mechanical ventilation and ICU and/or hospital length of stay.
      Keywords: Respiratory infections and tuberculosis
      PubDate: 2020-02-12T00:09:10-08:00
      DOI: 10.1183/16000617.0107-2019
      Issue No: Vol. 29, No. 155 (2020)
  • Impact of CFTR modulator use on outcomes in people with severe cystic
           fibrosis lung disease

    • Authors: Shteinberg, M; Taylor-Cousar, J. L.
      Pages: 190112 - 190112
      Abstract: Drug compounds that augment the production and activity of the cystic fibrosis (CF) transmembrane regulator (CFTR) have revolutionised CF care. Many adults and some children with CF suffer advanced and severe lung disease or await lung transplantation. While the hope is that these drug compounds will prevent lung damage when started early in life, there is an ongoing need to care for people with advanced lung disease. The focus of this review is the accumulating data from clinical trials and case series regarding the benefits of CFTR modulator therapy in people with advanced pulmonary disease. We address the impact of treatment with ivacaftor, lumacaftor/ivacaftor, tezacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor on lung function, pulmonary exacerbations, nutrition and quality of life. Adverse events of the different CFTR modulators, as well as the potential for drug–drug interactions, are discussed.
      Keywords: CF and non-CF bronchiectasis
      PubDate: 2020-03-20T03:42:55-07:00
      DOI: 10.1183/16000617.0112-2019
      Issue No: Vol. 29, No. 155 (2020)
  • Community-acquired pneumonia in critically ill very old patients: a
           growing problem

    • Authors: Cilloniz, C; Dominedo, C, Pericas, J. M, Rodriguez-Hurtado, D, Torres, A.
      Pages: 190126 - 190126
      Abstract: Very old (aged ≥80 years) adults constitute an increasing proportion of the global population. Currently, this subgroup of patients represents an important percentage of patients admitted to the intensive care unit. Community-acquired pneumonia (CAP) frequently affects very old adults. However, there are no specific recommendations for the management of critically ill very old CAP patients. Multiple morbidities, polypharmacy, immunosenescence and frailty contribute to an increased risk of pneumonia in this population. CAP in critically ill very old patients is associated with higher short- and long-term mortality; however, because of its uncommon presentation, diagnosis can be very difficult. Management of critically ill very old CAP patients should be guided by their baseline characteristics, clinical presentation and risk factors for multidrug-resistant pathogens. Hospitalisation in intermediate care may be a good option for critical ill very old CAP patients who do not require invasive procedures and for whom intensive care is questionable in terms of benefit.
      Keywords: Epidemiology, occupational and environmental lung disease, Respiratory infections and tuberculosis
      PubDate: 2020-02-19T00:05:15-08:00
      DOI: 10.1183/16000617.0126-2019
      Issue No: Vol. 29, No. 155 (2020)
  • Clinical phenotyping: role in treatment decisions in sarcoidosis

    • Authors: Baughman, R. P; Scholand, M. B, Rahaghi, F. F.
      Pages: 190145 - 190145
      Abstract: A variety of phenotypic categorisations have been developed for sarcoidosis. Phenotyping has been used for genetics studies and to guide treatment selection. The authors participated in a Delphi expert consensus panel to develop a proposed phenotype categorisation and treatment recommendations for pulmonary sarcoidosis patients. Panellists reached consensus that asymptomatic patients with normal pulmonary function and adenopathy alone or normal chest imaging do not require therapy, while symptomatic patients with impaired pulmonary function or infiltrates should be treated. The panel did not reach consensus on asymptomatic patients with abnormal chest imaging or reduced pulmonary function, or symptomatic patients with normal chest imaging and pulmonary function. The proposed phenotype categories and associated treatment recommendations are asymptomatic (no therapy), acute (disease duration
      Keywords: Interstitial and orphan lung disease
      PubDate: 2020-03-20T03:42:55-07:00
      DOI: 10.1183/16000617.0145-2019
      Issue No: Vol. 29, No. 155 (2020)
  • Delphi consensus recommendations for a treatment algorithm in pulmonary

    • Authors: Rahaghi, F. F; Baughman, R. P, Saketkoo, L. A, Sweiss, N. J, Barney, J. B, Birring, S. S, Costabel, U, Crouser, E. D, Drent, M, Gerke, A. K, Grutters, J. C, Hamzeh, N. Y, Huizar, I, Ennis James, W, Kalra, S, Kullberg, S, Li, H, Lower, E. E, Maier, L. A, Mirsaeidi, M, Müller-Quernheim, J, Carmona Porquera, E. M, Samavati, L, Valeyre, D, Scholand, M. B.
      Pages: 190146 - 190146
      Abstract: Pulmonary sarcoidosis presents substantial management challenges, with limited evidence on effective therapies and phenotypes. In the absence of definitive evidence, expert consensus can supply clinically useful guidance in medicine. An international panel of 26 experts participated in a Delphi process to identify consensus on pharmacological management in sarcoidosis with the development of preliminary recommendations.The modified Delphi process used three rounds. The first round focused on qualitative data collection with open-ended questions to ensure comprehensive inclusion of expert concepts. Rounds 2 and 3 applied quantitative assessments using an 11-point Likert scale to identify consensus.Key consensus points included glucocorticoids as initial therapy for most patients, with non-biologics (immunomodulators), usually methotrexate, considered in severe or extrapulmonary disease requiring prolonged treatment, or as a steroid-sparing intervention in cases with high risk of steroid toxicity. Biologic therapies might be considered as additive therapy if non-biologics are insufficiently effective or are not tolerated with initial biologic therapy, usually with a tumour necrosis factor-α inhibitor, typically infliximab.The Delphi methodology provided a platform to gain potentially valuable insight and interim guidance while awaiting evidenced-based contributions.
      Keywords: Interstitial and orphan lung disease
      PubDate: 2020-03-20T03:42:55-07:00
      DOI: 10.1183/16000617.0146-2019
      Issue No: Vol. 29, No. 155 (2020)
  • Management of repository corticotrophin injection therapy for pulmonary
           sarcoidosis: a Delphi study

    • Authors: Rahaghi, F. F; Sweiss, N. J, Saketkoo, L. A, Scholand, M. B, Barney, J. B, Gerke, A. K, Lower, E. E, Mirsaeidi, M, O'Hare, L, Rumbak, M. J, Samavati, L, Baughman, R. P.
      Pages: 190147 - 190147
      Abstract: In patients treated with repository corticotrophin injection (RCI) for pulmonary sarcoidosis, effective management of adverse events may improve adherence. However, management of adverse events may be challenging due to limitations in real-world clinical experience with RCI and available published guidelines.We surveyed 12 physicians with a modified Delphi process using three questionnaires. Questionnaire 1 consisted of open-ended questions. Panellists' answers were developed into a series of statements for Questionnaires 2 and 3. In these, physicians rated their agreement with the statements using a Likert scale.Key consensus recommendations included a starting dose of 40 units twice a week for patients with less severe disease, continued at a maintenance dose for patients who responded, particularly those with chronic refractory sarcoidosis. Panellists reached consensus that concomitant steroids should be quickly tapered in patients receiving RCI, but that concomitant use of immunosuppressive medications should be continued. Panellists developed consensus recommendations for adverse event management, and reached consensus that RCI should be down-titrated or discontinued if other interventions for the adverse effects fail or if the adverse effect is severe.In the absence of clinical evidence, our Delphi consensus opinions may provide practical guidance to physicians on the management of RCI to treat pulmonary sarcoidosis.
      Keywords: Interstitial and orphan lung disease
      PubDate: 2020-03-20T03:42:55-07:00
      DOI: 10.1183/16000617.0147-2019
      Issue No: Vol. 29, No. 155 (2020)
  • "Is bronchiectasis really a disease'" Michal Shteinberg, Patrick A.
           Flume and James D. Chalmers. Eur Respir Rev 2020; 29: 190051.

    • Pages: 195051 - 195051
      PubDate: 2020-02-12T00:09:10-08:00
      DOI: 10.1183/16000617.5051-2019
      Issue No: Vol. 29, No. 155 (2020)
  • "How can we minimise the use of regular oral corticosteroids in
           asthma'" Arnaud Bourdin, Ian Adcock, Patrick Berger, Philippe
           Bonniaud, Philippe Chanson, Cecile Chenivesse, Jacques de Blic, Antoine
           Deschildre, Philippe Devillier, Gilles Devouassoux, Alain Didier, Gilles
           Garcia, Antoine Magnan, Yan Martinat, Thierry Perez, Nicolas Roche,
           Camille Taille, Pierre Val and Pascal Chanez. Eur Respir Rev 2020; 29:

    • Pages: 195085 - 195085
      PubDate: 2020-02-12T00:09:10-08:00
      DOI: 10.1183/16000617.5085-2019
      Issue No: Vol. 29, No. 155 (2020)
  • Natural enemy or friend' Pneumonia in the very elderly critically ill

    • Authors: Niederman; M. S.
      Pages: 200031 - 200031
      Abstract: Pneumonia has been a serious cause of morbidity and mortality for many years and, more than 100 years ago, Sir William Osler referred to it as "the natural enemy of the old man" [1]. Many studies have documented that elderly individuals have a higher frequency of illness, increased mortality and more subtle clinical features compared to younger populations. This too was known by Osler who commented that "it is not improbable that debility lowers the vitality and renders the individual susceptible" and when the illness occurs, it can be "without chill; the cough and expectoration are slight" and the physical findings non-specific [1]. He noted that while fever was not usually prominent, patients often had altered mental status and that pneumonia could precipitate congestive heart failure [1].
      Keywords: Epidemiology, occupational and environmental lung disease, Respiratory infections and tuberculosis
      PubDate: 2020-02-19T00:05:15-08:00
      DOI: 10.1183/16000617.0031-2020
      Issue No: Vol. 29, No. 155 (2020)
  • Modulator treatment for people with cystic fibrosis: moving in the right

    • Authors: Elborn; J. S.
      Pages: 200051 - 200051
      Abstract: In the past 10 years the incremental success of modulators of the cystic fibrosis transmembrane regulator (CFTR) protein have improved outcomes for people with cystic fibrosis (CF) [1]. Ivacaftor for individuals with sequence variants associated with class III mutations (e.g. G551D) and some other residual function mutations of the CFTR gene followed by lumacaftor/ivacaftor or tezacaftor/ivacaftor combinations in individuals homozygous for the F508del have achieved improvements in quality of life reduction, pulmonary exacerbations and variable improvement in forced expiratory volume in 1 s (FEV1). Highly effective modulator treatment, a triple combination of tezacaftor/ivacaftor and elexacaftor (a second modulator with the CFTR potentiator), was granted market approval in October 2019 by the US Food and Drug Administration. This approval is "for patients 12 years and older with CF who have at least one F508del mutation in the CFTR gene, which is estimated to represent 90% of the CF population" [2].
      Keywords: CF and non-CF bronchiectasis
      PubDate: 2020-03-20T03:42:55-07:00
      DOI: 10.1183/16000617.0051-2020
      Issue No: Vol. 29, No. 155 (2020)
  • European Respiratory Review, list of peer reviewers 2019

    • Pages: 515120 - 515120
      Abstract: The European Respiratory Review is voluntarily reviewed. We are most grateful to the hard work and dedication of those listed below, who reviewed articles for the ERR in 2019
      PubDate: 2020-01-29T00:05:04-08:00
      DOI: 10.1183/16000617.5151-2020
      Issue No: Vol. 29, No. 155 (2020)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-